---
title: WFSBP Guidelines for Bipolar Disorder
organization: World Federation of Societies of Biological Psychiatry (WFSBP)
year: 2023
category: bipolar
---

# WFSBP Guidelines for Biological Treatment of Bipolar Disorder

## Acute Mania

### First-Line Monotherapy (Evidence A):
1. **Mood Stabilizers**:
   - Lithium (0.6-1.2 mEq/L)
   - Valproate (50-125 mcg/mL)

2. **Second-Generation Antipsychotics**:
   - Aripiprazole, asenapine, cariprazine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone

3. **Typical Antipsychotic**:
   - Haloperidol

### First-Line Combination Therapy (Evidence A):
- **Lithium or valproate + antipsychotic** (superior to monotherapy)
- Preferred for severe mania or mixed features

### Second-Line:
- Carbamazepine
- ECT (especially catatonic features or treatment resistance)
- Tamoxifen (experimental)

### Not Recommended as Monotherapy:
- Antidepressants (risk of switch to mixed state or rapid cycling)
- Lamotrigine (not effective for acute mania)
- Gabapentin, topiramate

## Acute Bipolar Depression

### First-Line (Evidence A):
1. **Quetiapine** (300-600 mg/day)
2. **Olanzapine-fluoxetine combination (OFC)**
3. **Lurasidone** (20-120 mg with ≥350 cal meal)
4. **Lithium** (0.6-1.0 mEq/L)
5. **Lamotrigine** (up to 200 mg/day - slow titration limits acute use)

### First-Line Combination (Evidence A-B):
- **Lithium or valproate + SSRI** (escitalopram, fluoxetine, paroxetine)
- **Lithium + lamotrigine**

### Second-Line:
- Cariprazine, aripiprazole (moderate evidence)
- Valproate
- ECT (severe or treatment-refractory)
- Modafinil, pramipexole (adjunctive)

### Antidepressants:
- **NEVER as monotherapy** (risk of manic switch ~30%)
- **Only in combination** with mood stabilizer or antipsychotic
- Prefer bupropion or SSRIs (lower switch risk than SNRIs/TCAs)
- Duration: Taper after 2-3 months if possible

## Mixed Episodes

### First-Line:
- Valproate
- Olanzapine, quetiapine, asenapine, aripiprazole, cariprazine
- Lithium (less effective than in pure mania)

### Avoid:
- Antidepressants (can worsen mixed states)

## Maintenance Treatment

### Goals:
- Prevent recurrence (both manic and depressive episodes)
- Continue ≥2 years after first episode; indefinitely after multiple episodes

### First-Line Monotherapy (Evidence A):
1. **Lithium** (most evidence; anti-suicidal effects)
2. **Quetiapine**
3. **Lamotrigine** (especially prevention of depressive episodes)
4. **Valproate**
5. **Aripiprazole, olanzapine, paliperidone, risperidone**

### First-Line Combination (Evidence A-B):
- **Lithium + valproate**
- **Lithium or valproate + quetiapine**
- **Lithium + lamotrigine**

### Maintenance After Manic Episode:
- Continue antimanic agent (lithium, valproate, or antipsychotic)

### Maintenance After Depressive Episode:
- Lithium or lamotrigine preferred
- Quetiapine effective for both poles

### Long-Acting Injectable (LAI) Antipsychotics:
- Aripiprazole monohydrate, paliperidone palmitate, risperidone
- Consider for adherence issues

## Rapid Cycling Bipolar Disorder

### Definition:
≥4 mood episodes per year

### Treatment:
1. **Optimize mood stabilizer** (lithium or valproate to therapeutic levels)
2. **Add lamotrigine or quetiapine**
3. **Discontinue antidepressants** (may contribute to cycling)
4. **Treat comorbid conditions**: Hypothyroidism, substance use

## Special Populations

### Women of Childbearing Potential:
**AVOID Valproate**: Teratogenic (neural tube defects 10%, cognitive impairment)

**Preferred Options**:
- Lamotrigine (lowest teratogenic risk)
- Quetiapine
- Lithium (lower risk than previously thought; Ebstein anomaly ~0.05%)

**Pregnancy**:
- Continue treatment if possible (relapse risk 50-70% if stopped)
- High-dose folate supplementation (5 mg/day)
- Detailed fetal ultrasound if exposed to mood stabilizers

### Elderly:
- Lower doses of mood stabilizers (lithium 0.4-0.8 mEq/L)
- Monitor renal function, thyroid, drug interactions
- Antipsychotics: Lower doses, monitor for EPS and metabolic effects

## Monitoring Requirements

### Lithium:
- **Levels**: Every 3-6 months (target 0.6-1.0 mEq/L maintenance)
- **Renal function** (Cr, eGFR): Baseline, 6 months, then annually
- **Thyroid** (TSH, free T4): Baseline, 6 months, then annually
- **Calcium**: Baseline, then annually
- **ECG**: If cardiac risk factors or age >50

### Valproate:
- **Levels**: Target 50-125 mcg/mL
- **LFTs, CBC**: Baseline, then every 6-12 months
- **Avoid in women of childbearing potential**

### Antipsychotics:
- **Weight, BMI, waist circumference**: Baseline, monthly x3, then quarterly
- **Glucose, lipids**: Baseline, 3 months, then annually
- **Prolactin** (if risperidone, paliperidone, amisulpride): If symptoms
- **Movement disorders** (AIMS): Every 6-12 months

### Lamotrigine:
- No routine monitoring required
- Educate about rash (SJS/TEN risk - stop immediately if rash)

## Psychosocial Interventions

### Recommended Adjuncts:
- Psychoeducation (all patients)
- CBT, interpersonal and social rhythm therapy (IPSRT)
- Family-focused therapy

## Sources
- Grunze H, et al. WFSBP Guidelines for Biological Treatment of Bipolar Disorders: Update 2023 on maintenance treatment. World J Biol Psychiatry. 2023.
- WFSBP Bipolar Guidelines 2023
